Cargando…

Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer

Selpercatinib, a RET kinase inhibitor, is an effective treatment for patients with medullary thyroid cancer with RET mutations. In this paper, we present the case of a 62-year-old man with ectopic Cushing’s syndrome due to medullary thyroid cancer who received treatment with selpercatinib. Six month...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ragnarsson, Oskar, Piasecka, Marta, Hallqvist, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139362/ https://www.ncbi.nlm.nih.gov/pubmed/35621672 http://dx.doi.org/10.3390/curroncol29050282

Ejemplares similares

Ectopic Cushing’s Syndrome and Severe Hypocalcemia Due to Medullary Thyroid Cancer Responsive to Selpercatinib
por: Turin, Christie Gloria, et al.
Publicado: (2021)

Rapid and long-lasting response to selpercatinib of paraneoplastic Cushing’s syndrome in medullary thyroid carcinoma
por: Sitbon, Marine, et al.
Publicado: (2022)

Is ectopic Cushing’s syndrome underdiagnosed in patients with small cell lung cancer?
por: Piasecka, Marta, et al.
Publicado: (2022)

Neoadjuvant selpercatinib for advanced medullary thyroid cancer
por: Jozaghi, Yelda, et al.
Publicado: (2020)

ODP477 Ectopic Cushing's Syndrome Due to Medullary Thyroid Cancer
por: Mateen, Abdul, et al.
Publicado: (2022)

Metastatic medullary thyroid carcinoma presenting as ectopic Cushing’s syndrome
por: Forde, Hannah E, et al.
Publicado: (2021)

Unusual increase in carcinoembryonic antigen despite response to selpercatinib in two patients with medullary thyroid cancer
por: Bardet, Stéphane, et al.
Publicado: (2022)

Sporadic Medullary Thyroid Carcinoma with Paraneoplastic Cushing Syndrome
por: Pivovarova, Aleksandra I., et al.
Publicado: (2019)

Simultaneous ectopic adrenocorticotropic hormone syndrome and adrenal metastasis of a medullary thyroid carcinoma causing paraneoplastic Cushing's syndrome
por: Sand, Michael, et al.
Publicado: (2007)

Medullary Thyroid Carcinoma with Ectopic Adrenocorticotropic Hormone Syndrome
por: Choi, Hong Seok, et al.
Publicado: (2014)

Functional brain alterations in Cushing’s syndrome
por: Papakokkinou, Eleni, et al.
Publicado: (2023)

Ectopic Cushing’s syndrome due to a mesenteric neuroendocrine tumour
por: Mashoori, N, et al.
Publicado: (2012)

Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect
por: Højer Wang, Linnea, et al.
Publicado: (2023)

Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea
por: Baek, Han-Sang, et al.
Publicado: (2023)

Cushing’s syndrome due to ectopic adrenocorticotropin secretion by a parotid carcinoma
por: Antonacio, Fernanda F., et al.
Publicado: (2022)

Vandetanib induces a marked anti-tumor effect and amelioration of ectopic Cushing’s syndrome in a medullary thyroid carcinoma patient
por: Bseiso, Hashem, et al.
Publicado: (2016)

Successful Management of Cushing Syndrome From Ectopic ACTH Secretion in an Adolescent With Osilodrostat
por: Blew, Kathryn, et al.
Publicado: (2023)

LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer
por: Wirth, Lori J, et al.
Publicado: (2022)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases
por: Andreev-Drakhlin, Alexander, et al.
Publicado: (2020)

Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma
por: Werner, Rudolf A., et al.
Publicado: (2022)

Severe Cushing Syndrome Due to Ectopic ACTH Secretion by Pheochromocytoma
por: Giorgi, Rafael Buck, et al.
Publicado: (2021)

Ectopic Cushing’s syndrome due to adrenocorticotropic hormone secreting atypical thymic carcinoid tumor
por: Duran, Cevdet, et al.
Publicado: (2018)

A Challenging Case of an Ectopic Cushing Syndrome
por: Menezes Nunes, Joana, et al.
Publicado: (2014)

Ectopic Cushing's Syndrome Secondary to Metastatic Paraganglioma
por: Daya, R., et al.
Publicado: (2021)

Mifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing's Syndrome
por: Moraitis, Andreas G., et al.
Publicado: (2016)

Ectopic Cushing syndrome in Colombia
por: Lopez-Montoya, Vanessa, et al.
Publicado: (2020)

Fluconazole treatment in severe ectopic Cushing syndrome
por: Canteros, Teresa M, et al.
Publicado: (2019)

Mental Fatigue and Executive Dysfunction in Patients with Cushing's Syndrome in Remission
por: Papakokkinou, Eleni, et al.
Publicado: (2015)

Ectopic ACTH Production Leading to Diagnosis of Underlying Medullary Thyroid Carcinoma
por: Matheny, Leslee N., et al.
Publicado: (2016)

Cushing's Syndrome due to Ectopic ACTH from Bronchial Carcinoid: A Case Report and Review
por: Kenchaiah, Manohara, et al.
Publicado: (2012)

Ectopic Cushing’s syndrome secondary to olfactory neuroblastoma
por: Yu, Kenny, et al.
Publicado: (2018)

Long-term Treatment With Metyrapone in a Man With Ectopic Cushing Syndrome
por: Wong, Tin Wai
Publicado: (2022)

Ectopic Cushing’s syndrome from a corticotropin-releasing hormone-secreting medullary thyroid carcinoma: a rare pitfall of inferior petrosal sinus sampling
por: Mäkinen, Vivi-Nelli, et al.
Publicado: (2023)

Cushing's syndrome due to ectopic ACTH production by a nasal paraganglioma
por: Serra, F, et al.
Publicado: (2013)

Adrenocorticotropic Hormone-Secreting Esthesioneuroblastoma with Ectopic Cushing's Syndrome
por: Chung, Young Soo, et al.
Publicado: (2020)

Clival Ectopic Pituitary Adenoma Causing Cushing Syndrome
por: Karthik, Subramaniam, et al.
Publicado: (2023)

Lenvatinib and selpercatinib successfully treated RET fusion gene-positive papillary thyroid carcinoma cardiac metastases: a case report
por: Toda, Soji, et al.
Publicado: (2023)

Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA
por: Della Corte, C.M., et al.
Publicado: (2021)

Selpercatinib Treatment of RET-Mutated Thyroid Cancers Is Associated With Gastrointestinal Adverse Effects
por: Tsang, Venessa, et al.
Publicado: (2022)

Selpercatinib: First Approval
por: Markham, Anthony
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4eqr29civ7hqc1eo2bl95v7vj5